Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecobalamin plus anti-VEGF for retinal vein occlusion macular edema
ChiCTR2500108682Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Vein occlusion (RVO) comparing Test group (mecobalamin + conbercept) with Control group (placebo + conbercept) (2 arms). Primary endpoint: central foveal thickness at 12 months. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
mecobalamin
03
Conditions
Vein occlusion (RVO)
Beyond the preview
Go deeper on ChiCTR2500108682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108682.